Posts filed under ‘Inmunizaciones’

Interventions to Reduce Measles Virus Exposures in Outpatient Health Care Facilities — New York City, 2018

MMWR Sep 13, 2019 V.68 N.36 P.794-792

Strengthening health care facility infection control is crucial to preventing infectious disease transmission.

Guidelines to prevent or minimize airborne pathogen spread in outpatient health care facilities exist (1); however, few reports describe practical implementation when engineering controls, such as recommended airborne infection isolation rooms (negative pressure rooms), are unavailable* (2).

On September 30, 2018, a person with measles, a highly contagious respiratory illness characterized by fever and rash, that is spread by airborne transmission, was detected in New York City (NYC),† and as of December 10, 42 laboratory or epidemiologically linked cases had been confirmed.

By September 3, 2019, with 654 confirmed cases, this measles outbreak had become the largest in the United States since 1992, well before endemic domestic measles transmission was declared eliminated in 2000§,¶ (3,4).

Interventions used in 15 outpatient health care facilities to attempt to prevent health care facility exposure from patients with suspected measles were evaluated….




September 20, 2019 at 3:54 pm

ARGENTINA – Confirmación de tres nuevos casos de sarampión en niños. Alto riesgo de transmisibilidad

ACTUALIZACIÓN EPIDEMIOLÓGICA 13/0/2019 – Ministerio salud Nación

En virtud de la situación epidemiológica regional y local respecto a la confirmación de tres casos de

sarampión en niños residentes de la Ciudad Autónoma de Buenos Aires y la Provincia de Buenos Aires, la

Secretaria de Gobierno de Salud emite la siguiente actualización…..



– – –

September 14, 2019 at 9:39 am

Sep. 11, 2019 Confirmación de dos casos de sarampión en viajeros. Alto riesgo de transmisibilidad Ministerio Salud Argentina


En virtud de la situación del brote de sarampión en Brasil y otros países de la región y el mundo, y la confirmación de dos casos en turistas extranjeros arribados a España provenientes de Argentina con diagnóstico de sarampión, la Secretaria de Gobierno de Salud emite la siguiente actualización …

Boletín completo

September 12, 2019 at 7:54 am

Confirmación de caso de sarampión en Ciudad de Buenos Aires con antecedente de viaje a Brasil

ALERTA EPIDEMIOLÓGICA 4/Septiembre/2019 – SE 36

En virtud de la situación de brote de sarampión en Brasil y otros países de la región y el mundo, y la confirmación de un caso en un ciudadano argentino con antecedente de viaje, la Secretaría de Gobierno de Salud emite el presente alerta:


Se confirmó un caso de sarampión en un hombre de 44 años residente en la Ciudad de Buenos Aires, atendido en efector privado, con antecedente de viaje a Brasil, que comenzó con fiebre el día 10 de agosto, agregando exantema cuatro días después. El caso se confirmó por serología (IgM positiva en suero) y seroconversión de IgG, así como RT-PCR positiva en orina. Las muestras fueron procesadas por el efector privado y se confirmaron en el Laboratorio Nacional de Referencia ANLIS Carlos G. Malbrán. Se encuentran en desarrollo las pruebas para identificación de genotipo y linaje viral. La fuente de infección está en investigación. Se iniciaron acciones de prevención y control en los contactos del caso, quienes se encuentran en seguimiento…


September 9, 2019 at 3:10 pm

Intraoperative povidone-iodine irrigation for infection prevention

Arthroplasty Today September 2019 V.5 N.3 P.306-308

Although prevention of infection following arthroplasty requires a multifaceted approach, the use of intraoperative irrigation is an important component of any protocol.

Recent clinical practice guidelines from the Centers for Disease Control, World Health Organization, and International Consensus Meeting on Musculoskeletal Infection advocate the use of a dilute povidone-iodine solution prior to wound closure.

Our experience suggests that this practice is safe, inexpensive, and easily implemented.

The present article describes our institutional irrigation protocol and reviews the current literature regarding povidone-iodine solutions.



September 6, 2019 at 8:17 am

Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females 

npj Vaccines 2019 V.4 N.29


Vaccine-induced immunity declines with age, which may differ between males and females. Using human sera collected before and 21 days after receipt of the monovalent A/Cal/09 H1N1 vaccine, we evaluated cytokine and antibody responses in adult (18–45 years) and aged (65+ years) individuals. After vaccination, adult females developed greater IL-6 and antibody responses than either adult males or aged females, with female antibody responses being positively associated with concentrations of estradiol. To test whether protection against influenza virus challenge was greater in females than males, we primed and boosted adult (8–10 weeks) and aged (68–70 weeks) male and female mice with an inactivated A/Cal/09 H1N1 vaccine or no vaccine and challenged with a drift variant A/Cal/09 virus. As compared with unvaccinated mice, vaccinated adult, but not aged, mice experienced less morbidity and better pulmonary viral clearance following challenge, regardless of sex. Vaccinated adult female mice developed antibody responses that were of greater quantity and quality and more protective than vaccinated adult males. Sex differences in vaccine efficacy diminished with age in mice. To determine the role of sex steroids in vaccine-induced immune responses, adult mice were gonadectomized and hormones (estradiol in females and testosterone in males) were replaced in subsets of animals before vaccination. Vaccine-induced antibody responses were increased in females by estradiol and decreased in males by testosterone. The benefit of elevated estradiol on antibody responses and protection against influenza in females is diminished with age in both mice and humans.


August 30, 2019 at 7:49 am

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.

MMWR Morb Mortal Wkly Rep. August 16, 2019 V.68 N.32 P.698-702.

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE.


Vaccination against human papillomavirus (HPV) is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers.

The Advisory Committee on Immunization Practices (ACIP)* routinely recommends HPV vaccination at age 11 or 12 years; vaccination can be given starting at age 9 years.

Catch-up vaccination has been recommended since 2006 for females through age 26 years, and since 2011 for males through age 21 years and certain special populations through age 26 years.

This report updates ACIP catch-up HPV vaccination recommendations and guidance published in 2014, 2015, and 2016 (1-3). Routine recommendations for vaccination of adolescents have not changed. In June 2019, ACIP recommended catch-up HPV vaccination for all persons through age 26 years.

ACIP did not recommend catch-up vaccination for all adults aged 27 through 45 years, but recognized that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range; therefore, ACIP recommended shared clinical decision-making regarding potential HPV vaccination for these persons.




August 29, 2019 at 10:54 am

Older Posts


October 2019
« Sep    

Posts by Month

Posts by Category